Victory Capital Management
PTGX icon

Victory Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Victory Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
83,883
+339
+0.4% +$35.4K 0.01% 1103
2026
Q1 		$8.81M Buy
83,544
+2,973
+4% +$263K 0.01% 1120
2025
Q4 		$7.04M Sell
80,571
-4,923
-6% -$403K ﹤0.01% 1174
2025
Q3 		$5.68M Sell
85,494
-5,438
-6% -$309K ﹤0.01% 1302
2025
Q2 		$5.03M Sell
90,932
-11,479
-11% -$551K ﹤0.01% 1322
2025
Q1 		$4.95M Sell
102,411
-138,406
-57% -$5.8M 0.01% 1283
2024
Q4 		$9.3M Buy
240,817
+110,020
+84% +$4.8M 0.01% 1108
2024
Q3 		$5.89M Buy
130,797
+123,647
+1,729% +$5M 0.01% 1235
2024
Q2 		$248K Sell
7,150
-58
-0.8% -$1.7K ﹤0.01% 2149
2024
Q1 		$209K Buy
+7,208
New +$196K ﹤0.01% 2213
2022
Q1 		– Sell
-9,612
Closed -$329K – 2795
2021
Q4 		$329K Buy
+9,612
New +$304K ﹤0.01% 2351
2021
Q3 		– Sell
-845,199
Closed -$37.9M – 2835
2021
Q2 		$37.9M Buy
+845,199
New +$27.9M 0.04% 667
2020
Q2 		– Sell
-3,326
Closed -$23K – 3087
2020
Q1 		$23K Buy
+3,326
New +$24.9K ﹤0.01% 2795
2019
Q4 		– Sell
-3,250
Closed -$39K – 3109
2019
Q3 		$39K Buy
+3,250
New +$41K ﹤0.01% 2795

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Victory Capital Management's PTGX Position: Q2 2026 in Review

Victory Capital Management increased its Protagonist Therapeutics (PTGX) stake by 0.41% in Q2 2026, buying an estimated $35.4K and bringing the position to 83,883 shares worth $10.3M. The position accounts for 0.01% of the portfolio, ranked #1103.

Victory Capital Management first reported a position in PTGX in Q3 2019 and has held it in 14 quarters since. The position peaked at $37.9M in Q2 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Victory Capital Management held 83,883 shares of Protagonist Therapeutics worth $10.3M as of Q2 2026.
  • Victory Capital Management bought 339 Protagonist Therapeutics shares in Q2 2026, an estimated $35.4K.
  • Protagonist Therapeutics made up 0.01% of Victory Capital Management's portfolio in Q2 2026, its #1103 holding.
  • Victory Capital Management first reported a position in Protagonist Therapeutics in Q3 2019 and has held it in 14 quarters since.
  • Victory Capital Management's Protagonist Therapeutics position peaked at $37.9M in Q2 2021.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.